The findings provide the first direct evidence for the involvement of EC JAM-C in development of experimental ovarian cancer and indicate that this could be accounted for by a previously unknown function of EC JAM-C as a regulator of morphologically and functionally viable blood vessels. The gene discussed is JAM3; the disease is ovarian cancer.